UNH remains a Hold as margin recovery supports preserving exposure but insufficient upside-payoff justifies adding at current levels
Maintain UNH as an actively managed Hold. Existing holders preserve core exposure; do not add above $400 or at current levels. Reduce to Underweight on weekly close below $349.61, material Q3 MLR miss with prior-authorization cost creep, or Medicare Advantage net membership loss above 3%. Upgrade to Overweight only after one of the stated entry or fundamental confirmation triggers.
| Position | Action |
|---|---|
| Below $360-$380 pullback zone | Add exposure |
| At or above $400 | Do not add |
UNH is only two quarters into a multi-quarter recovery from a known trough (Change Healthcare cyber fallout + elevated MLR), trading at 17.9x forward P/E in line with peers, with defensive characteristics that outperform in the current macro environment and a credible October 1 catalyst that extends the Optum moat — making the risk/reward favor the bull.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 349.61 | bullish |
| close_50_sma | 411.20 | bearish |
| close_10_ema | 397.67 | bullish |
| macd | -2.92 | bearish |
| macds | -4.27 | bearish |
| macdh | +1.35 | bullish |
| rsi | 49.99 | neutral |
| boll | 396.52 | neutral |
| boll_ub | 407.12 | neutral |
| boll_lb | 385.91 | neutral |
| atr | 8.98 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Operating margins inflected dramatically from trough, not lagging — 0.34% to 7.13% in two quarters represents a margin inflection, not a lag
↩ rebuts: “Margins haven't kept pace with the price recovery (Trefis argument)”
EV: +12–20% · concedes: 50 SMA reclaim not yet confirmed — failure to break $407 in next 1–2 sessions would push back into $386–$411 range-bound regime; MLR discipline must hold post-October 1 — if medical costs spike after prior-auth removal, the EPS recovery narrative breaks; Multiple expansion is largely complete — further upside has to come from earnings beats, not valuation reratings; Q3 earnings (mid-October) is binary — a miss would deflate the recovery thesis quickly
UNH at $400 is a distribution opportunity priced for flawless recovery execution, with the stock already at fair value versus peers despite decelerating sequential earnings, a margin-peaking trajectory, and binary Q3 catalysts carrying more downside than upside risk.
EV: -$4 to -$8 · concedes: The cyberattack trough was severe, making the recovery path technically real; Free cash flow is recovering and now at $16.1B annually; The stock is above the 200 SMA, technically in long-term uptrend; The prior-auth announcement removes a regulatory compliance burden; H1 2026 EPS of $12.94 did exceed full-year 2025 EPS of $13.23 on a half-year basis
→ vs conservative: 40% recovery from $3-4B cyberattack trough is fundamentally different from momentum spike; operating margins legitimately inflected to 7-8% range from 0.34% trough
→ vs conservative: 50 SMA at $411 is only 2.5% above price—lagging indicator that shouldn't override leading fundamental signals at inflection points
→ vs conservative: Calling stock 'fully valued' using TTM P/E of 25.7x is anchoring to trough earnings; forward P/E of 17.9x with normalized EPS of $22.44 is fairly/attractively valued
→ vs conservative: Don't sell recovery after two consecutive strong quarters (Q1/Q2 2026) because of 92bps sequential wobble between them
→ vs neutral: Macro is 'actively bullish,' not 'neutral-to-supportive'—93% zero-cuts odds, $100 oil, 78% Hormuz disruption creates years-long defensive rotation tailwind, not months
→ vs neutral: Burry accumulation is 'confirmation,' not curiosity—high-conviction deep-value investor buying upside in stock you own means lean in, not shrug
→ vs neutral: 'Wait for confirmation' framework (close above 407, 431, Q3 margin expansion) costs the 20% upside to $480; you'll enter after the move and sell into consolidation while institutions accumulate from you
→ vs neutral: Retail silence (1 r/stocks mention, zero WSB, zero r/investing) signals institutional accumulation, not neutral sentiment
| vwma | 395.17 | bullish |
Support: 386 · 385.91 · 383.83 | Resistance: 407 · 407.12 · 411 · 411.2
UNH is consolidating near $400.84 after a sharp pullback from ~$431 (mid-July) to ~$384.85 (Aug-20). Long-term trend remains bullish above the 200 SMA at 349.61, but medium-term is weakened with price ~2.5% below the 50 SMA at 411.20. Short-term momentum is mildly constructive with price above the 10 EMA (397.67), positive MACD histogram (+1.35), and RSI neutral at 49.99. Near-term consolidation is expected between lower Bollinger Band (385.91) and upper band (407.12), with a HOLD recommendation pending a breakout above $407 or pullback to $386–$390 for new entries.
Market Cap
$359.79B
Revenue (TTM)
$450.5B
Gross Profit
$88.86B
EBITDA
$26.68B
Net Income
$14.12B
EPS (TTM)
$15.57
Forward EPS
$22.44
P/E (TTM)
25.74
Forward P/E
17.87
PEG Ratio
1.08
P/B
3.68
Dividend Yield
2.34%
Beta
0.622
52-Week High
$461.62
52-Week Low
$255.97
50-Day Avg Price
$411.74
200-Day Avg Price
$351.49
Operating Margin
7.13%
Profit Margin
3.14%
ROE
14.15%
ROA
4.87%
Free Cash Flow
$24.27B
FCF Yield
~6.7%
Total Revenue (2025)
$447,567M
Total Revenue (2024)
$400,278M
Total Revenue (2023)
$371,622M
Net Income (2025)
$12,056M
Net Income (2024)
$14,405M
Net Income (2023)
$22,381M
Diluted EPS (2025)
$13.23
Diluted EPS (2024)
$15.51
Diluted EPS (2023)
$23.86
Operating Income (2025)
$18,964M
EBITDA (2025)
$23,060M
Interest Expense (2025)
$4,002M
Total Assets (2025)
$309,581M
Total Debt (2025)
$78,389M
Net Debt (2025)
$54,024M
Goodwill
$110,499M
Tangible Book Value
($36,863M)
Net Debt / EBITDA
~2.3x
Operating Cash Flow (2025)
$19,697M
Free Cash Flow (2025)
$16,075M
Acquisitions (2025)
$4,509M
Share Buybacks (2025)
$5,545M
Dividends (2025)
$7,916M
Strengths
Concerns
Recommendation: HOLD. UnitedHealth Group is fairly valued with a forward P/E of 17.87x in line with managed care peers, as the market has largely priced in the earnings recovery already. The stock trades ~14% above its 200-day moving average with limited margin of safety at current levels. While Q1-Q2 2026 results show strong operational recovery with margins rebounding to 7-8% and FCF of $18.4B in just two quarters, risks remain balanced including regulatory headwinds, cyberattack litigation exposure, elevated medical costs, and a full valuation. A pullback toward the 200-day MA ($351) or decisive break above $461 (52-week high) would provide better entry/exit signals.
Macro: Fed on hold with 93% probability of zero rate cuts in 2026; 8% US recession odds; Strait of Hormuz disruption at 78% probability with oil near $100/barrel; 10Y Treasury support broken per IBD tape — classic late-cycle rotation favoring defensives including managed care.